Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Nuvation Bio (NUVB-WT) Research & Development (2023 - 2025)

Nuvation Bio (NUVB-WT) has disclosed Research & Development for 3 consecutive years, with $34.3 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 17.06% to $34.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $115.1 million through Dec 2025, up 16.13% year-over-year, with the annual reading at $115.1 million for FY2025, 16.13% up from the prior year.
  • Research & Development for Q4 2025 was $34.3 million at Nuvation Bio, up from $28.8 million in the prior quarter.
  • The five-year high for Research & Development was $34.3 million in Q4 2025, with the low at $12.8 million in Q1 2024.
  • Average Research & Development over 3 years is $23.8 million, with a median of $26.0 million recorded in 2025.
  • The sharpest move saw Research & Development crashed 31.64% in 2024, then soared 91.57% in 2025.
  • Over 3 years, Research & Development stood at $15.4 million in 2023, then surged by 90.86% to $29.3 million in 2024, then rose by 17.06% to $34.3 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $34.3 million, $28.8 million, and $27.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.